(NASDAQ: ABSI) Absci's forecast annual revenue growth rate of 188.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Absci's revenue in 2025 is $4,534,000.On average, 5 Wall Street analysts forecast ABSI's revenue for 2025 to be $2,203,894,916, with the lowest ABSI revenue forecast at $713,069,767, and the highest ABSI revenue forecast at $4,208,384,965. On average, 5 Wall Street analysts forecast ABSI's revenue for 2026 to be $7,996,568,104, with the lowest ABSI revenue forecast at $1,426,139,534, and the highest ABSI revenue forecast at $19,398,426,347.
In 2027, ABSI is forecast to generate $13,912,627,828 in revenue, with the lowest revenue forecast at $9,295,373,751 and the highest revenue forecast at $20,144,602,925.